Figure S5 from Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors Is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Cancer

This is a Experimental Study study.

Key Points

Combination treatment significantly enhances efficacy against pancreatic cancer cells lacking MTAP.
Analysis showed synergistic effects between PRMT5 inhibitors and KRAS inhibitors in vitro.
This approach opens new avenues for targeted therapies in specific pancreatic cancer genotypes.
Further studies are necessary for clinical validation and effectiveness assessments in human trials.

We only have this paper's title and publication details.

In vitro analysis reveals effective combination treatment for MTAP-deleted KRAS-mutant pancreatic cancer, suggesting new therapeutic strategies.

Figure S5 shows PRMT5i and pan-RASi combination treatment analysis in vitro.

No takes yet. Share an insight, caveat, or question.

Drizyte‐Miller et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Share